Featured Research

from universities, journals, and other organizations

Mesothelioma: A targeted approach to asbestos-related cancer

Date:
September 10, 2013
Source:
BioMed Central Limited
Summary:
A new targeted therapy for asbestos-related tumors has shown promise in an animal model. The results raise hopes of a new therapy for this currently incurable cancer. Malignant mesothelioma (MMs) is a rare form of cancer, most commonly caused by exposure to asbestos. It tends to be diagnosed decades after exposure occurs, so is rarely caught early. Current treatments, including surgery and chemotherapy, have limited efficacy and unpleasant side effects.

A new targeted therapy for asbestos-related tumours has shown promise in an animal model. The results, reported in the open access journal BMC Cancer, raise hopes of a new therapy for this currently incurable cancer.

Related Articles


Malignant mesothelioma (MMs) is a rare form of cancer, most commonly caused by exposure to asbestos. It tends to be diagnosed decades after exposure occurs, so is rarely caught early. Current treatments, including surgery and chemotherapy, have limited efficacy and unpleasant side effects.

Traditional chemotherapeutic drugs work by destroying cells that divide quickly. As such, they're indiscriminate killers, destroying healthy dividing cells such as those in the bone marrow, digestive tract and hair follicles, as well as cancer cells. The result is an unwelcome mix of side-effects including a weakened immune system, gastrointestinal problems and hair loss. Targeted therapies, which are designed to kill cancer cells and leave healthy tissue unharmed, are highly sought after.

The new targeted therapy is a silica microparticle, coated in antibodies that recognise a protein produced by the tumour cells in large amounts. When the microparticles are injected into a mouse model of the cancer, the antibody helps the microparticles bind to the tumour cells, where they are then able to release their hidden inner cargo -- the chemotherapy drug doxorubicin.

The new therapy is more effective and less toxic than doxorubicin alone, Brooke T. Mossman and colleagues report. Tumours shrank, the cancer cells proliferated less, and the animals were able more or less to maintain their weight and health throughout the treatment. Overall, the data suggest that targeted therapy may prove better than chemotherapy alone.

Using this targeting approach, the authors were able to reduce the dose of doxorubicin used four-fold thus almost eliminating side effects and toxicity. And because the treatment appears to reduce the number of proliferating tumour cells, it may prove useful early on, when pre-malignant or malignant MM cells are first observed, but before disease has been confirmed by histology.


Story Source:

The above story is based on materials provided by BioMed Central Limited. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sherrill L Macura, Jeremy L Steinbacher, Maximilian B MacPherson, Melissa J Lathrop, Mutlay Sayan, Jedd M Hillegass, Stacie L Beuschel, Timothy N Perkins, Page C Spiess, Albert van der Vliet, Kelly J Butnor, Arti Shukla, Marilyn Wadsworth, Christopher C Landry and Brooke T Mossman. Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts. BMC Cancer, 2013 DOI: 10.1186/1471-2407-13-400

Cite This Page:

BioMed Central Limited. "Mesothelioma: A targeted approach to asbestos-related cancer." ScienceDaily. ScienceDaily, 10 September 2013. <www.sciencedaily.com/releases/2013/09/130910205319.htm>.
BioMed Central Limited. (2013, September 10). Mesothelioma: A targeted approach to asbestos-related cancer. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2013/09/130910205319.htm
BioMed Central Limited. "Mesothelioma: A targeted approach to asbestos-related cancer." ScienceDaily. www.sciencedaily.com/releases/2013/09/130910205319.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins